Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,665 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed/Refractory ALL Clear all

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Interventions: ARD103, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: ARCE Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas

Conditions: Pancreatic Carcinoma, Tumors That Express CA 19-9
Interventions: MVT-1075, MVT-5873; Drug
Lead sponsor: BioNTech Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Scottsdale, Arizona • New York, New York

Conditions: Multiple Myeloma
Interventions: ACY-1215 in combination with pomalidomide and dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Dallas, Texas • San Antonio, Texas • Salt Lake City, Utah

Conditions: T Cell Lymphoma, T-cell Lymphoma
Interventions: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • New York, New York

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Ibrutinib, Obinutuzumab; Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: Nivolumab; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Lymphoma
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 9 more

Conditions: Lymphoma
Interventions: arsenic trioxide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 17 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma
Interventions: Istodax, Doxil; Drug
Lead sponsor: Weiyun Ai; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: cytarabine, laromustine; Drug
Lead sponsor: Vion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Radiation
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Belleville, New Jersey

Conditions: Lymphoma, Non-Hodgkin
Interventions: GSK5926371; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Iowa City, Iowa • New York, New York • Canton, Ohio

Conditions: Multiple Myeloma in Relapse
Interventions: Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia
Interventions: GO-203-2c, GO-203-2c + Decitabine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions: AVL-292; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: HDP-101; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more

Conditions: Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Multiple Myeloma, Lymphocytic Leukemia, Myeloproliferative Disorder, Polycythemia Vera, Myelofibrosis, Aplastic Anemia
Interventions: fludarabine/busulfan, fludarabine/ melphalan, ATG; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 10 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions: Crenolanib, Mitoxantrone, Cytarabine, Etoposide, Fludarabine, G-CSF, Idarubicin; Drug
Lead sponsor: Arog Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Little Rock, Arkansas • Duarte, California • Dallas, Texas + 1 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: SPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Lymphoma, Leukemia
Interventions: CPI-613; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 11
States / cities: Duarte, California • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more

Conditions: T-cell Lymphoma
Interventions: CPI-818; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 3 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Mezigdomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 33
States / cities: Mobile, Alabama • Cerritos, California • Irvine, California + 28 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions: Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Samotolisib, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 125
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more

Search by objective public record fields.

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)